|Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies|
L Fattore, E Marra, ME Pisanu, A Noto, C De Vitis, F Belleudi, ...
Journal of translational medicine 11 (1), 180, 2013
|MicroRNAs in melanoma development and resistance to target therapy|
L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ...
Oncotarget 8 (13), 22262, 2017
|miR-579-3p controls melanoma progression and resistance to target therapy|
L Fattore, R Mancini, M Acunzo, G Romano, A Laganą, ME Pisanu, ...
Proceedings of the National Academy of Sciences 113 (34), E5005-E5013, 2016
|Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer|
A Noto, C De Vitis, G Roscilli, L Fattore, D Malpicci, E Marra, L Luberto, ...
Oncotarget 4 (8), 1253, 2013
|Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells|
F Belleudi, E Marra, F Mazzetta, L Fattore, MR Giovagnoli, R Mancini, ...
Cell Cycle 11 (7), 1455-1467, 2012
|Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma|
L Fattore, D Malpicci, E Marra, F Belleudi, A Noto, C De Vitis, ME Pisanu, ...
Oncotarget 6 (28), 24823, 2015
|TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung|
A Ricci*, C De Vitis*, A Noto*, L Fattore, S Mariotta, E Cherubini, G Roscilli, ...
Cell cycle 12 (11), 1696-1703, 2013
|Selective targeting of point-mutated KRAS through artificial microRNAs|
M Acunzo, G Romano, G Nigita, D Veneziano, L Fattore, A Laganą, ...
Proceedings of the National Academy of Sciences 114 (21), E4203-E4212, 2017
|Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR)|
P Costanzo, A Santini, L Fattore, E Novellino, A Ritieni
Food and Chemical Toxicology 76, 77-79, 2015
|Role of WT1–ZNF224 interaction in the expression of apoptosis-regulating genes|
G Montano, E Cesaro, L Fattore, K Vidovic, C Palladino, R Crescitelli, ...
Human molecular genetics 22 (9), 1771-1782, 2013
|Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma|
L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ...
Cell Death & Differentiation 26 (7), 1267-1282, 2019
|MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma|
L Fattore, A Sacconi, R Mancini, G Ciliberto
Cytokine & growth factor reviews 36, 39-48, 2017
|Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma|
ME Pisanu, M Maugeri-Saccą, L Fattore, S Bruschini, C De Vitis, E Tabbģ, ...
Journal of Experimental & Clinical Cancer Research 37 (1), 1-17, 2018
|Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists|
DA Fitzmaurice, G Accetta, S Haas, G Kayani, H Lucas Luciardi, ...
British journal of haematology 174 (4), 610-623, 2016
|Melanoma and immunotherapy bridge 2015|
VGY Nanda, W Peng, P Hwu, MA Davies, G Ciliberto, L Fattore, ...
Journal of Translational Medicine 14 (1), 65, 2016
|miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma|
L Fattore, M Acunzo, G Romano, A Laganą, D Malpicci, ME Pisanu, ...
Cancer Research 76 (14 Supplement), 1070-1070, 2016
|ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors|
L Fattore, D Malpicci, E Marra, R Camerlingo, G Roscilli, F Belleudi, ...
Journal of translational medicine 13 (S1), K3, 2015
|CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions|
S Bruschini, S di Martino, ME Pisanu, L Fattore, C De Vitis, V Laquintana, ...
Journal of cellular physiology 235 (3), 1877-1887, 2020
|Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study|
L De Luca, PL Temporelli, C Riccio, L Gonzini, L Marinacci, ...
European Heart Journal-Quality of Care and Clinical Outcomes 5 (4), 334-342, 2019
|The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma|
L Fattore, R Mancini, PA Ascierto, G Ciliberto
Expert opinion on therapeutic targets 23 (1), 53-68, 2019